Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc.
Bullboard Posts
User Avatar Image
(0)
•••
Comment by francois21on Jan 02, 2015 2:09pm
369 Views
Post# 23280398

RE:RE:RE:Hybridan raises its base case valuation to $3.37!

RE:RE:RE:Hybridan raises its base case valuation to $3.37!
You will find above the sum of the part value from Hybridan report. Very interesting to see:

ProMetic: Sum of the Parts Value ProMetic: 
 
C$ m Value 
 
Protein Technology $266.0 Peer 7x sales multiple 
 
Biopharmaceut icals $652.3 1.1m capacity inc GENERIUM 
 
Therapeutics $678.0 Galectin 
 
Corporate costs -$20.0 
 
NantPro 266.5 Risked NPV 
 
Total Enterprise Value 1842.8 
 
Net Debt 4.6
 
Total Equity Value $1838.2 
 
Implied price per share C$ 3.37
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities